Slovenia Pharmaceuticals & Healthcare Report Q1 2016 - New Study Released

From: Fast Market Research, Inc.
Published: Tue Nov 10 2015

Slovenia, similar to most Central and Eastern European (CEE) countries, currently has limited capabilities in managing its rare disease population and we expect that EU authorities will push the country into accelerating its implementation of the necessary infrastructure to manage this patient subgroup. While Slovenia has adopted a national strategy and has a more progressive attitude towards orphan drug reimbursement than many of its CEE peers, it cur r ently lacks crucial elements needed to manage these populations. It i s an area where Slovenia's healthcare system will need to expand coverage to deliver better patient outcomes.

Headline Expenditure Projections

Pharmaceuticals: EUR675mn (USD896mn) in 2014 to EUR671mn (USD738mn) in 2015; -0.6% in local currency terms and -17.6% in US dollar terms. Forecasts unchanged compared to previous quarter.
Healthcare: EUR3.22bn (USD4.27bn) in 2014 to EUR3.23bn (USD3.55bn) in 2015; 0.4% in local currency terms and -16.8% in US dollar terms. Forecasts unchanged compared to previous quarter.

Full Report Details at

BMI Risk/Reward Index

Slovenia scores 50.4 out of a total of 100 in our Pharmaceutical Risk/Reward Index for Q415 - down from 51.6 in the previous quarter. This places the country 10th in our index of 20 countries and above the average for the region, which is 49.3.

Key Trends & Developments

The Slovenia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Slovenia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovenia pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Slovenia, to test other views - a key input for successful budgeting and strategic business planning in the Slovenian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Slovenian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Slovenia.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.


BMI Industry View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Algeria Pharmaceuticals & Healthcare Report Q1 2016
- Australia Pharmaceuticals & Healthcare Report Q1 2016
- Croatia Pharmaceuticals & Healthcare Report Q1 2016
- Puerto Rico Pharmaceuticals & Healthcare Report Q1 2016
- Estonia Pharmaceuticals & Healthcare Report Q4 2015

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »